文献速递临床试验与 GCP流行病学与生物统计真实世界研究与卫生经济

缅甸村庄卫生志愿者网络分发驱蚊剂预防疟疾的阶梯楔形集群随机试验

Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks against Plasmodium spp. infection in Myanmar: A stepped-wedge cluster randomised trial.
PubMed 文献 · PLoS Med · 2020-08-20

该研究在缅甸116个村庄开展15个月阶梯楔形集群随机试验,评估村庄卫生志愿者分发12%驱蚊剂对疟原虫感染的效果。结果显示驱蚊剂对快速诊断试验阳性感染无显著保护,但对PCR检测的恶性疟原虫感染有保护作用,对间日疟原虫无显著保护。

要点

  • 驱蚊剂对PCR检测的恶性疟原虫感染有保护作用(ARRR=0.67)。
  • 对快速诊断试验阳性感染无显著保护(AOR=0.25)。
  • 对PCR检测的间日疟原虫感染无显著保护(ARRR=1.41)。

核心结论

  • 村庄卫生志愿者大规模分发驱蚊剂对恶性疟原虫新发感染显示一定保护作用,可考虑纳入国家疟疾消除策略。

研究设计与样本

  • 2015年4月至2016年6月在缅甸116个村庄开展15个月阶梯楔形集群随机试验,每月分块推进。
  • 参与者中位年龄18岁,约半数女性,多数为村民(46%)或森林居民(40%)。
  • 干预为村庄卫生志愿者分发12% N,N-二乙基苯甲酰胺(DEET)乳膏。

主要发现

  • 快速诊断试验检测的总体疟原虫感染率为0.16%(50/32,194)。
  • PCR检测的总体疟原虫感染率为3%(419/13,157)。
  • 对快速诊断试验可检测感染无显著保护(AOR=0.25,95%CI 0.004-15.2,p=0.512)。
  • 对PCR检测的恶性疟原虫感染有保护作用(ARRR=0.67,95%CI 0.47-0.95,p=0.026)。
  • 对PCR检测的间日疟原虫感染无显著保护(ARRR=1.41,95%CI 0.80-2.47,p=0.233)。

关键数值与推荐

  • 增量成本效果比为每避免一例PCR检测感染256美元。
  • 研究期间未报告不良事件。

临床怎么用

  • 在蚊帐效果较差地区可考虑将驱蚊剂纳入国家疟疾消除策略。
  • 需在不同传播环境和人群中进一步研究以支持WHO公共卫生政策。

局限性

  • 实际疟原虫感染率低于预期。
  • 干预可能存在地理稀释效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization has yet to endorse deployment of topical repellents for malaria prevention as part of public health campaigns. We aimed to quantify the effectiveness of repellent distributed by the village health volunteer (VHV) network in the Greater Mekong Subregion (GMS) in reducing malaria in order to advance regional malaria elimination. METHODS AND FINDINGS: Between April 2015 and June 2016, a 15-month stepped-wedge cluster randomised trial was conducted in 116 villages in Myanmar (stepped monthly in blocks) to test the effectiveness of 12% N,N-diethylbenzamide w/w cream distributed by VHVs, on Plasmodium spp. infection. The median age of participants was 18 years, approximately half were female, and the majority were either village residents (46%) or forest dwellers (40%). No adverse events were reported during the study. Generalised linear mixed modelling estimated the effect of repellent on infection detected by rapid diagnostic test (RDT) (primary outcome) and polymerase chain reaction (PCR) (secondary outcome). Overall Plasmodium infection detected by RDT was low (0.16%; 50/32,194), but infection detected by PCR was higher (3%; 419/13,157). There was no significant protection against RDT-detectable infection (adjusted odds ratio [AOR] = 0.25, 95% CI 0.004-15.2, p = 0.512). In Plasmodium-species-specific analyses, repellent protected against PCR-detectable P. falciparum (adjusted relative risk ratio [ARRR] = 0.67, 95% CI 0.47-0.95, p = 0.026), but not P. vivax infection (ARRR = 1.41, 95% CI 0.80-2.47, p = 0.233). Repellent effects were similar when delayed effects were modelled, across risk groups, and regardless of village-level and temporal heterogeneity in malaria prevalence. The incremental cost-effectiveness ratio was US$256 per PCR-detectable infection averted. Study limitations were a lower than expected Plasmodium spp. infection rate and potential geographic dilution of the intervention. CONCLUSIONS: In this study, we observed apparent protection against new infections associated with the large-scale distribution of repellent by VHVs. Incorporation of repellent into national strategies, particularly in areas where bed nets are less effective, may contribute to the interruption of malaria transmission. Further studies are warranted across different transmission settings and populations, from the GMS and beyond, to inform WHO public health policy on the deployment of topical repellents for malaria prevention. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry (ACTRN12616001434482).

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Agius PA, Cutts JC, Han Oo W, et al. Evaluation of the effectiveness of topical repellent distributed by village health volunteer networks against Plasmodium spp. infection in Myanmar: A stepped-wedge cluster randomised trial. PLoS Med. 2020. PMID: 32817632. doi:10.1371/journal.pmed.1003177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。